Granza Bio
Reprogramming Immunity for Target-Specific Medicines
Synthetic Biology
Biotech
Healthcare
Therapeutics
Oncology
About
Granza Bio is building on the discovery of a previously unknown cytotoxic mechanism in T cells: supramolecular attack particles (SMAPs, Science 2020). This biology reveals a new modality through which cytotoxic lymphocytes deliver persistent, high-intensity killing.
Build your own investing agent
GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.
Join the GPAgent waitlistDetails
Status
Active
Stage
Early
Team Size
7
Regions
United States of America, America / Canada